EGFR and non-small cell lung carcinoma: Afatinib, the second-generation EGFR TKI, has been demonstrated to inhibit EGFR T790M-resistant mutation irreversibly in animal models and NSCLC patients, but its poor selectivity toward wild-type EGFR could result in severe side effects at the clinical stage (Edwards et al., 2018).